Rosuvastatin drug interactions
Pro Research Analysisby 
Searched over 200M research papers
Key Transporters in Rosuvastatin Drug Interactions: BCRP and OATP
Rosuvastatin drug interactions are mainly driven by drug transporters rather than cytochrome P450 enzymes. The most important transporters involved are the breast cancer resistance protein (BCRP) and organic anion transporting polypeptides (OATP), especially OATP1B1, OATP1B3, and OATP2B1. Inhibition of BCRP in the gut can significantly increase rosuvastatin absorption, leading to higher blood levels of the drug. In contrast, inhibition of OATP1B1 and OATP1B3 in the liver can also increase rosuvastatin exposure, but to a lesser extent compared to BCRP inhibition. OATP2B1 plays a role in oral absorption, and its inhibition can sometimes decrease rosuvastatin levels, depending on the balance with BCRP inhibition West2025Wang2017Elsby2023+3 MORE.
Clinically Significant Drug Interactions with Rosuvastatin
BCRP Inhibitors
Drugs that inhibit BCRP, such as fostamatinib and certain protease inhibitors (e.g., atazanavir, lopinavir, ritonavir), can cause up to a two-fold increase in rosuvastatin exposure. This is considered clinically significant and may require dose adjustment of rosuvastatin to avoid side effects Elsby2023Elsby2016. The effect is mainly due to increased absorption in the intestine when BCRP is blocked.
OATP Inhibitors
Strong inhibitors of OATP1B1 and OATP1B3, such as rifampin and cyclosporine, can also increase rosuvastatin levels, but the effect is generally less pronounced than with BCRP inhibition. For example, rifampin and cyclosporine can increase rosuvastatin area under the curve (AUC) by about 5- to 6-fold, mainly through hepatic transporter inhibition Wang2017Hanke2021. Some drugs, like ronacaleret and elagolix, can actually decrease rosuvastatin exposure if they inhibit OATP2B1 more strongly than BCRP .
Other Commonly Used Drugs
- Telmisartan and Amlodipine: When taken with rosuvastatin, these drugs slightly increase rosuvastatin exposure, but the change is not considered clinically significant .
- Olmesartan: Co-administration with rosuvastatin does not significantly affect the pharmacokinetics of either drug, and any changes are not clinically important .
- Ezetimibe: Combined use with rosuvastatin is well tolerated and does not result in clinically significant interactions .
- Tacrolimus: In animal studies, tacrolimus does not significantly alter rosuvastatin pharmacokinetics, but mild liver toxicity was observed. In clinical models, no major interaction is predicted .
Mechanisms and Clinical Implications
The main mechanism behind rosuvastatin drug interactions is the inhibition of transporters that control its absorption and elimination. BCRP inhibition in the gut leads to higher rosuvastatin absorption, while OATP inhibition in the liver reduces its clearance. These interactions are not related to cytochrome P450 enzymes, which means rosuvastatin has fewer interactions with drugs that affect these enzymes compared to other statins .
Safety and Tolerability
Most drug interactions with rosuvastatin are mild and do not require changes in therapy, except when strong BCRP or OATP inhibitors are used. In these cases, monitoring and possible dose adjustment of rosuvastatin are recommended to avoid side effects such as muscle toxicity Son2016Roh2014Kim2018.
Conclusion
Rosuvastatin drug interactions are mainly caused by drugs that inhibit the BCRP and OATP transporters. BCRP inhibitors can significantly increase rosuvastatin levels, while OATP inhibitors have a variable effect depending on the specific transporter involved. Most other commonly used drugs, such as telmisartan, amlodipine, olmesartan, and ezetimibe, do not cause clinically significant interactions with rosuvastatin. Understanding these mechanisms helps guide safe and effective use of rosuvastatin in combination therapy.
Sources and full results
Most relevant research papers on this topic